Project Grant R44CA310370
Award Date 9/8/25
Completion Date 8/31/27
Dollars Obligated $992K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
- The federal Project Grant award R01CA289387, totaling $657,121.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to develop a novel dendritic cell therapy for treating leptomeningeal disease (LMD), a severe complication that occurs in 5% of advanced-stage breast cancer patients. The research aims to...
- This federal Project Grant award of $778,092.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy approach for treating high-grade serous ovarian cancer. The award was made to the Dana-Farber Cancer Institute, Inc. (DFCI), a leading cancer research and treatment center in Boston, MA, on April 15, 2025, with a planned completion date of April 14,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
- The federal Project Grant award titled "DLL3-TARGETED IL18-SECRETING CAR T CELLS IN SMALL CELL LUNG CANCER" was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $716,521.00 on August 25, 2025. The award supports a research project conducted by the Sloan-Kettering Institute for Cancer Research in New York to determine the safety and preliminary efficacy of DLL3-targeted, IL18-secreting chimeric antigen receptor (CAR) T cells for the...
- The federal Project Grant award titled "HARNESSING B CELLS AFTER STEM CELL TRANSPLANT TO PRODUCE NOVEL CAR-TS" is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a total of $415,257. The project period runs from July 3, 2025 to June 30, 2027. The award aims to leverage insights into B cell tolerance mechanisms after hematopoietic stem cell transplantation to engineer less toxic, more targeted immune cells that can eradicate hematological...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $818,625 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct a randomized trial evaluating cardioprotective strategies for patients with diffuse large B-cell lymphoma (DLBCL) who have pre-existing cardiomyopathy or prior anthracycline exposure. The primary objective is to determine whether the infusional cardioprotective strategies of dexrazoxane or liposomal doxorubicin...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This $2,660,756 federal Project Grant award from the Department of Defense's Defense Health Agency supports research on "GENOMIC AND IMMUNOMIC MECHANISMS OF RESISTANCE DURING DARATUMUMAB POST STEM CELL TRANSPLANTATION IN PATIENTS WITH POOR-RISK T CELL LYMPHOBLASTIC LYMPHOMA LEUKEMIA". It is funded under the Military Medical Research and Development program (CFDA 12.420), which focuses on biomedical research to address health conditions affecting service members and veterans. The...
- The Defense Health Agency awarded a $1,598,801 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a Phase 1B study of the BCL-XL degrader DT2216 combined with paclitaxel in recurrent platinum-resistant ovarian cancer. This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members and the public. The study aims to investigate the efficacy of...
- This $1,124,607 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a Phase 2 multi-center clinical trial of a novel CD5 chimeric antigen receptor (CAR) T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The grant, awarded from July 1, 2025 to June 30, 2027, will validate the safety and efficacy of the improved MB-105 product, which has demonstrated promising results in...